共查询到2条相似文献,搜索用时 0 毫秒
1.
2.
Taylor PL 《Science and engineering ethics》2005,11(4):589-616
Key ethical issues arise in association with the conduct of stem cell research by research institutions in the United States.
These ethical issues, summarized in detail, receive no adequate translation into federal laws or regulations, also described
in this article. U.S. Federal policy takes a passive approach to these ethical issues, translating them simply into limitations
on taxpayer funding, and foregoes scientific and ethical leadership while protecting intellectual property interests through
a laissez faire approach to stem cell patents and licenses. Those patents and licenses, far from being scientifically and
ethically neutral in effect, virtually prohibit commercially sponsored research that could otherwise be a realistic alternative
to the federal funding gap. The lack of federal funding and related data-sharing principles, combined with the effect of U.S.
patent policy, the lack of key agency guidance, and the proliferation of divergent state laws arising from the lack of Federal
leadership, significantly impede ethical stem cell research in the United States, without coherently supporting any consensus
ethical vision. Research institutions must themselves implement steps, described in the article, to integrate addressing ethical
review with the many legal compliance issues U.S. federal and state laws create.
The opinions expressed in this article are the author’s own, and are not necessarily the opinions of others, including Children’s
Hospital Boston. Portions of earlier versions of this article were previously published by the American Bar Association and
the New York State Bar Association. 相似文献